{"id":"nct:NCT03614650","kind":"trial","title":"Immunotherapy Treating GI Cancer","authors":["Shenzhen Geno-Immune Medical Institute"],"author_count":1,"year":2018,"published":"2018-08-03","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT03614650","source_url":"https://clinicaltrials.gov/study/NCT03614650","archive_url":"https://space-kitty.com/papers/nct:NCT03614650","updated":"2026-08-26","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"The primary objectives are to evaluate the safety and efficacy of infusion of autologous gastro-intestinal (GI) cancer antigen-specific engineered immune effector cells (EIE).","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Cancer"],"details":{"acronym":null,"status":"NOT_YET_RECRUITING","phase":"PHASE1, PHASE2","study_type":"INTERVENTIONAL","enrollment":100,"sponsor":"Shenzhen Geno-Immune Medical Institute","conditions":["Cancer"],"interventions":["BIOLOGICAL: engineered immune cells"],"start_date":"2027-06-01","start_date_type":"ESTIMATED","primary_completion_date":"2028-06-30","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"gene-cell-therapy","name":"Gene & Cell Therapy","domain_slug":"medicine"}],"cited_in_dossiers":[]}